VIDEO: Oral roflumilast shows significant PASI reduction in plaque psoriasis treatment
Click Here to Manage Email Alerts
In this Healio video exclusive, Jashin J. Wu, MD, FAAD, of the University of Miami Miller School of Medicine, discusses a study following the use of oral roflumilast to treat plaque psoriasis.
The study by Alexander Egeberg, MD, PhD, and colleagues was presented at the American Academy of Dermatology Annual Meeting and was performed following the approval of topical roflumilast to treat psoriasis.
Study participants either received once-daily 500 µg roflumilast or placebo for 12 weeks, which was followed by all individuals receiving 500 µg roflumilast once a day for the following 12 weeks. There were 23 patients included in each arm of the study, and by week 12 there was a 61% reduction in PASI score.
About 83% of individuals taking roflumilast showed weight loss compared with 40% of those taking placebo. Also, 52% of individuals on the study drug reported nausea vs. 26% of those on placebo.
Reference:
- Egeberg A. Efficacy and safety of oral roflumilast in the treatment of moderate to severe psoriasis – a randomized, double-blinded, placebo-controlled trial (PSORRO). Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans.